CME Presentations

Adult Growth Hormone Deficiency


Presentations


Speakers

  • Kevin CJ Yuen, MD, FRCP (UK), FACE

    Kevin CJ Yuen, MD, FRCP (UK), FACE

    Kevin CJ Yuen, MD, FRCP (UK), FACE

    Professor of Medicine and Medical Director

    Kevin C.J. Yuen, MD, FRCP (UK), FACE, is professor of medicine and medical director of the Pituitary Center at the Barrow Neurological Institute in Phoenix, Arizona. His expertise includes clinical and research interest in managing hypothalamic-pituitary and adrenal disorders (particularly in adults with growth hormone deficiency), acromegaly, Cushing’s disease and adrenal insufficiency, and he is interested in neuroendocrine disorders in young adult cancer survivors and adults with traumatic brain injury. Dr Yuen is active in international collaborative studies and widely published, has authored several book chapters, serves on various medical committees, and frequently speaks on topics related to pituitary disorders. He received his MD from the University of Sheffield, United Kingdom.
  • Beverly M.K. Biller, MD, FACP

    Beverly M.K. Biller, MD, FACP

    Beverly M.K. Biller, MD, FACP

    Professor of Medicine

    Beverly M.K. Biller, MD, is a professor of medicine at Harvard Medical School (HMS) and a faculty member of the neuroendocrine unit at Massachusetts General Hospital (MGH) in Boston, where she directs the clinical fellowship in adult endocrinology and metabolism. She also directs the annual HMS and MGH Department of Continuing Education postgraduate course “Clinical Endocrinology”. Dr Biller’s major research interests include the pathogenesis, diagnosis and treatment of Cushing’s disease, acromegaly, prolactinomas, other pituitary tumors, and growth hormone deficiency in adults. She is on the AACE Task Force to Update the Growth Hormone Guidelines, the Endocrine Society’s Committee on Diversity and Inclusion, and is membership chair of the Growth Hormone Research Society.
  • Andrew R. Hoffman, MD

    Andrew R. Hoffman, MD

    Andrew R. Hoffman, MD

    Professor and Vice Chair, Department of Medicine

    Andrew R. Hoffman, MD, is professor and senior vice chair for academic affairs in the Department of Medicine at Stanford University School of Medicine in California and is the chief of endocrinology at the VA Palo Alto Health Care System. His laboratory research focuses on examining epigenetic mechanisms of gene expression and studying the role of insulin-like growth factors (IGF) and growth hormone in normal physiology and in cancer development. His studies have implications for the therapeutic use of growth hormone and IGF in development and in the clinical consequences of aging. Dr Hoffman is involved in clinical projects studying the natural history of bone health in elderly men, the role of testosterone replacement in middle-aged men, and neuroendocrine function in aging.

CME Information

Adult Growth Hormone Deficiency (GHD) – An Introduction to the New AACE Guidelines


  

LEARNING OBJECTIVES

Upon successful completion of this activity, participants should be better able to:

  • Explain the signs and symptoms of growth hormone deficiency
  • Evaluate evidence-based testing strategies for GHD
  • Design individualized treatment strategies

Course Start Date: 4/12/19

Course Expiration Date: 4/12/20


Program Description:

Growth hormone deficiency (GHD) affects more than 50,000 adults in the United States, with 6,000 new cases are reported each year (1). These cases include the continuation of child-onset GHD into adulthood and those caused by damage to the hypothalamic-pituitary axis. While adult onset GHD has been predominantly associated with oncologic causes and their treatment, an increasing number of adult GHD cases have been reported following traumatic brain injury (TBI). TBI represents a leading cause of death and disability in the United States (2) and greatly expands the number of patients at risk for GHD following motor vehicle accidents, falls, sports-related head traumas, combative sports, and veterans returning from combat service.

Adult GHD usually manifests as reduced physical performance and impaired psychological well-being. If left untreated, GHD can lead to insulin resistance, increased visceral fat, altered lipid metabolism, all of which contribute to increased cardiovascular morbidity and mortality rates. Patients with untreated GHD also exhibit reduced muscle, lean body mass, and bone mass. GHD, has been linked to diminished quality of life including reductions in mental and physical energy, dissatisfaction with body image, depression, and poor memory (3,4). The growing number of patients at risk for GHD and potentially serious clinical consequences of untreated adult GHD underlines the need for education among a broad spectrum of healthcare providers to ensure appropriate and timely diagnosis and treatment of GHD.

Target Audience

The intended audience for this activity consists of endocrinologists, primary care providers, neurologists, and psychiatrists.

Accreditation and Designation Statements:

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support:

This educational activity is supported by an educational grant from Novo Nordisk Pharmaceutical Company.

Learner Bill of Rights:

The American Association of Clinical Endocrinologists (AACE) recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill or performance. As part of AACE’s duty to you as a learner, you have the right to expect that your continuing medical education experience with AACE includes:

CONTENT that:

  • Promotes improvements or quality in healthcare;
  • Is Valid, reliable and accurate;
  • Offers balanced presentations that are free of commercial bias for or against a product/service;
  • Is vetted through a process that resolves any conflicts of interest of planners, teachers or authors;
  • Is driven and based on learning needs, not commercial interests;
  • Addresses the stated objectives or purpose; and
  • Is evaluated for its effectiveness in meeting the identified educational need.
  • A LEARNING ENVIRONMENT that:

  • Supports learners’ ability to meet their individual needs;
  • Respects and attends to any special needs of the learners;
  • Respects the diversity of groups of learners; and
  • Is free of promotional, commercial and/or sales activities.
  • DISCLOSURE of:

  • Relevant financial relationships planners, teachers and authors have with commercial interests related to the content of the activity; and
  • Commercial support (funding or in-kind resources) of the activity.
  • Method of Participation:

    There are no fees to participate int his activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 75% on the post-test.

    Estimated Time to Complete:

    This activity consists of one session which should take approximately 1 hours to complete.

    Hardware/Software Requirements:

    Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media

    Faculty:

    Kevin CJ Yuen, MD, FRCP (UK), FACE – Chair
    Professor of Medicine and Medical Director
    Barrow Pituitary Center
    Barrow Neurological Institute
    University of Arizona College of Medicine
    Creighton University School of Medicine
    Phoenix, AZ

    Andrew R. Hoffman, MD
    Professor and Vice Chair, Department of Medicine
    Stanford University School of Medicine
    Chief, Endocrinology Section
    VA Palo Alto Health Care System
    Palo Alto, CA

    Beverly M.K. Biller, MD, FACP
    Professor of Medicine, Harvard Medical School
    Neuroendocrine Unit, Massachusetts General Hospital
    Boston, MA

    Disclosure and Resolutions of Conflicts of Interest:

    It is the policy of AACE to ensure balance, independence, objectivity, and scientific rigor in all of its CME activities. Presentation content may include discussion of an unlabeled use of a commercial product or an investigational use of a product not yet approved for any purpose. AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest. AACE requires speakers, faculty, CME Committee, and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation, and educational materials used as basis for content, and appropriateness of patient care recommendations. The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments. Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence. AACE has reviewed all disclosures and resolved or managed all identified conflicts of interest for this educational activity, as applicable.

    CME Accreditation Committee Disclosures

       

    Commercial Interest

    Financial Relationship

    Myriam Allende-Vigo, MD, MBA, FACP, FACE 1.Abbott Laboratories
    2.Janssen Pharmaceuticals Inc.
    3.Merck & Co., Inc.
    1.Honorarium
    2.Honorarium
    3.Honorarium
    Tamis Bright, MD 1.Southwest ENT 1.Salary
    David S.H. Bell, MD, FACE, FACP 1.AstraZeneca
    2.Janssen Pharmaceuticals, Inc.
    3.Novo Nordisk A/S
    1.Honorarium
    2.Honorarium
    3.Honorarium
    Philip Raskin, MD, FACE 1.Amylin Pharmaceuticals 1.Research grant, payable to the University of Texas
    Joseph M. Tibaldi, MD, FACE 1.AstraZeneca
    2.Intacara
    3.Merck
    4.Novo Nordisk
    1.Honorarium
    2.Honorarium
    3.Honorarium
    4.Honorarium
    Dace L. Trence, MD, FACE 1.Medtronic, Inc.
    2.Sanofi-Aventis U.S. LLC.
    1.Stock
    2.Stock
    Jagdeesh Ullal, MD, FACE, ENCU 1.Corcept Therapeutics
    2.Shire
    3.Novo Nordisk
    1.Honorarium
    2.Honorarium
    3.Research Funding
    Jeff Unger, MD, FACE 1.Abbott Laboratories
    2.Janssen Pharmaceuticals, Inc.
    3.Novo Nordisk A/S
    4.Sanofi
    1.Honorarium
    2.Honorarium
    3.Honorarium
    4.Honorarium

    Nothing to Disclose

    Joshua I. Barzilay, MD, FACE

    Felice Caldarella, MD, FACP, CDE, FACE

    Richard Correa, MD

    Stephen Crespin, MD, FACE

    Phillip D.K. Lee, MD, FAAP, FACE

    Dorothy Martinez, MD, FACE

    Jad Sfeir, MD

    Program Committee Disclosures

    Program Committee Commercial Interest Financial Relationship
    Vin Tangpricha, MD, PhD
    Program Committee
    None None
    David C. Lieb, MD, FACP, FACE
    Program Committee
    None None
    Kevin CJ Yuen, MD, FRCP (UK), FACE
    Program Committee & Chair
    1. Strongbridge
    2. Corcept Therapeutics
    3. Sandoz
    4. Ionis Pharmaceuticals
    5. Aerterna Zentaris
    6. Pfizer
    7. Novo Nordisk
    8. Novartis
    1. Fees
    2. Fees
    3. Fees
    4. Research Grant
    5. Fees; Research Grant
    6. Fees; Research Grant
    7. Fees; Research Grant
    8. Fees; Research Grant

    Faculty Disclosures

    Faculty Commercial Interest Financial Relationship
    Kevin CJ Yuen, MD, FRCP (UK), FACE
    Chair & Faculty

    Reports that his presentation(s) will include discussion
    of long acting growth hormone products in the treatment of
    growth hormone replacement therapy.
    1. Strongbridge
    2. Corcept Therapeutics
    3. Sandoz
    4. Ionis Pharmaceuticals
    5. Aerterna Zentaris
    6. Pfizer
    7. Novo Nordisk
    8. Novartis
    1. Fees
    2. Fees
    3. Fees
    4. Research Grant
    5. Fees; Research Grant
    6. Fees; Research Grant
    7. Fees; Research Grant
    8. Fees; Research Grant
    Andrew R. Hoffman, MD
    Faculty

    Reports that his presentation(s) will include discussion
    of long acting growth hormone products in the treatment of
    adult growth hormone deficiency.
    1.Ascendis
    2.Cellerant
    3.GeneScience
    4.Genexine
    5.Merck
    6.Ono
    7.NovoNordisk
    8.Pfizer
    1.Fee
    2.Fee
    3.Fee
    4.Fee
    5.Fee
    6.Fee
    7.Honorarium
    8.Honorarium
    Beverly M.K. Biller, MD, FACP
    Faculty

    Reports that her presentation(s) may include discussion
    of the class of long-acting growth hormone preparations
    that are under development by a number of companies for
    the treatment of adult growth hormone deficiency.
    1.Aeterna Zentaris
    2.Ascendis
    3.Ferring
    4.Merck Serono
    5.Novo Nordisk
    6.OPKO Biologics
    7.Versartis
    1.Fees
    2.Fees
    3.Fees
    4.Fees
    5.Fees; Research Grant
    6.Fees; Research Grant
    7.Research Grant

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    The American Association of Clinical Endocrinologists (AACE) planners and managers have nothing to disclose.

    The PlatformQ Health Education, LLC planners and managers do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

    Disclosure of Unapproved/Off Label Use:

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Copyright Statement:

    Copyright 2018, AACE. All rights reserved. No part of this enduring material may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission from AACE.

    Acknowledgment:

    This activity is provided by the American Association of Clinical Endocrinologists (AACE). Program management services provided by PlatformQ.

    Disclaimer:

    The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    Technical Support:

    For any technical issues or issues with your CME Certificate, please contact ClincalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com